In an interview, Aditya Shreenivas, MD, MS, discussed the approval of penpulimab in nasopharyngeal carcinoma and the study ...

Manmeet Ahluwalia, MD, MBA, FASCO, discussed the significance of National Cancer Research Month and highlighted how ongoing ...

In an interview, Prof Martin Dreyling discussed the approval of first-line acalabrutinib for the treatment of adult patients ...

AI-assisted training notably improved pathologist accuracy in HER2-low breast cancer, reducing misclassification and ...

INAVO120 trial shows inavolisib, palbociclib, and fulvestrant significantly improved overall survival in PIK3CA-mutant ...

David P. Carbone, MD, PhD, discusses the outcomes of the phase 3 CheckMate 9LA trial in non–small cell lung cancer based on treatment discontinuation.

Anuradha Krishnamurthy, MBBS, discusses what physicians and patients must aware of regarding the safety of TIL therapy in melanoma.

Michael E. Kasper, MD, FACRO, discussed unmet needs in skin cancer treatment and addressed misconceptions among patients and ...

Long-term data confirms early rituximab significantly delays new treatment for advanced, asymptomatic, low-burden follicular ...

The ODAC deemed the results from TALAPRO-2 are not sufficient to conclude a favorable benefit-risk profile for adding ...

The FDA ODAC decided that the overall benefit-risk of the investigational therapy UGN-102 is not favorable in patients with ...

PT-112 monotherapy advances to phase 3 trial in metastatic castration-resistant prostate cancer after positive FDA end of ...